Current Editions
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
Product Development
RFK Jr. pushes out CBER director, one of the last veteran leaders of regulatory agency
Regulation
Cuts devised by acting commissioner with no input from center directors
Regulation
The FDA commissioner and NIH director are taking charge of agencies in crisis
Politics, Policy & Law
Emerging Company Profile
The Massachusetts-based company launched a microRNA-based liquid biopsy test for endometriosis, with an eye toward disease monitoring and drug development
Data Byte
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
At least eight East-to-West licensing deals outside oncology so far this year
Seven of 11 $1B+ immunology acquisitions focused on two diseases
Lilly to seek re-examination. Also in March meeting, CHMP backs label expansions for Opdivo, Tevimbra and more
Discovery & Translation
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
Regulation
Paul Kluetz and Marc Theoret, deputy directors of the Oncology Center of Excellence, have announced their resignations
Politics, Policy & Law
Industry is trying to head off sector-specific and country-based tariffs
Finance
Plus: Novo Holdings, Jeito lead week’s largest A round for VIB company Augustine — and more
Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Finance
Management Tracks
BioCentury ISSN 1097-7201